Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actinium-225 (225Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Trial Profile

Actinium-225 (225Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Lintuzumab Ac-225 (Primary) ; Plerixafor; Spironolactone
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2018 Preliminary data of the interim analysis (n=18) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Dec 2018 Results from the second cohort of the patients (n=27) presented in a media release.
    • 03 Dec 2018 According to a Actinium Pharmaceuticals media release, data from the second cohort of this study (n=27) were presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top